nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP1A1—Progesterone—uterine cancer	0.235	0.404	CbGbCtD
Dexmedetomidine—CYP1A2—Progesterone—uterine cancer	0.105	0.181	CbGbCtD
Dexmedetomidine—CYP2D6—Progesterone—uterine cancer	0.0865	0.149	CbGbCtD
Dexmedetomidine—CYP2E1—Etoposide—uterine cancer	0.0812	0.14	CbGbCtD
Dexmedetomidine—CYP1A2—Etoposide—uterine cancer	0.047	0.0809	CbGbCtD
Dexmedetomidine—CYP2D6—Doxorubicin—uterine cancer	0.0264	0.0454	CbGbCtD
Dexmedetomidine—ADRA1D—epithelium—uterine cancer	0.00219	0.0568	CbGeAlD
Dexmedetomidine—ADRA1B—renal system—uterine cancer	0.00208	0.0539	CbGeAlD
Dexmedetomidine—ADRA1D—female reproductive system—uterine cancer	0.00163	0.0422	CbGeAlD
Dexmedetomidine—ADRA2C—myometrium—uterine cancer	0.00153	0.0396	CbGeAlD
Dexmedetomidine—SLC6A2—decidua—uterine cancer	0.00128	0.0332	CbGeAlD
Dexmedetomidine—ADRA2A—myometrium—uterine cancer	0.00122	0.0316	CbGeAlD
Dexmedetomidine—ADRA2C—uterine cervix—uterine cancer	0.00119	0.0308	CbGeAlD
Dexmedetomidine—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00118	0.0031	CcSEcCtD
Dexmedetomidine—Chills—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00309	CcSEcCtD
Dexmedetomidine—Anaemia—Progesterone—uterine cancer	0.00116	0.00306	CcSEcCtD
Dexmedetomidine—Mental disorder—Medroxyprogesterone Acetate—uterine cancer	0.00114	0.00302	CcSEcCtD
Dexmedetomidine—Pneumonia—Dactinomycin—uterine cancer	0.00114	0.00301	CcSEcCtD
Dexmedetomidine—Malnutrition—Medroxyprogesterone Acetate—uterine cancer	0.00114	0.003	CcSEcCtD
Dexmedetomidine—ADRA2C—decidua—uterine cancer	0.00113	0.0294	CbGeAlD
Dexmedetomidine—ADRA2C—renal system—uterine cancer	0.00111	0.0289	CbGeAlD
Dexmedetomidine—Ventricular arrhythmia—Epirubicin—uterine cancer	0.00111	0.00293	CcSEcCtD
Dexmedetomidine—Neuritis—Epirubicin—uterine cancer	0.0011	0.00291	CcSEcCtD
Dexmedetomidine—Neuralgia—Doxorubicin—uterine cancer	0.0011	0.00289	CcSEcCtD
Dexmedetomidine—Convulsion—Progesterone—uterine cancer	0.00109	0.00286	CcSEcCtD
Dexmedetomidine—Hypertension—Progesterone—uterine cancer	0.00108	0.00285	CcSEcCtD
Dexmedetomidine—ADRA2C—endometrium—uterine cancer	0.00108	0.0279	CbGeAlD
Dexmedetomidine—Pleural effusion—Epirubicin—uterine cancer	0.00108	0.00283	CcSEcCtD
Dexmedetomidine—Anxiety—Progesterone—uterine cancer	0.00107	0.00281	CcSEcCtD
Dexmedetomidine—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.00105	0.00277	CcSEcCtD
Dexmedetomidine—Agitation—Medroxyprogesterone Acetate—uterine cancer	0.00105	0.00275	CcSEcCtD
Dexmedetomidine—Dry mouth—Progesterone—uterine cancer	0.00105	0.00275	CcSEcCtD
Dexmedetomidine—ADRA2C—mammalian vulva—uterine cancer	0.00104	0.027	CbGeAlD
Dexmedetomidine—Confusional state—Progesterone—uterine cancer	0.00103	0.00272	CcSEcCtD
Dexmedetomidine—Ventricular arrhythmia—Doxorubicin—uterine cancer	0.00103	0.00271	CcSEcCtD
Dexmedetomidine—CYP1A1—epithelium—uterine cancer	0.00103	0.0266	CbGeAlD
Dexmedetomidine—Neuritis—Doxorubicin—uterine cancer	0.00102	0.00269	CcSEcCtD
Dexmedetomidine—CYP1A1—uterine cervix—uterine cancer	0.00102	0.0264	CbGeAlD
Dexmedetomidine—Infection—Progesterone—uterine cancer	0.00102	0.00268	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Etoposide—uterine cancer	0.00101	0.00267	CcSEcCtD
Dexmedetomidine—Rigors—Epirubicin—uterine cancer	0.00101	0.00266	CcSEcCtD
Dexmedetomidine—SLC6A2—female reproductive system—uterine cancer	0.00101	0.0261	CbGeAlD
Dexmedetomidine—Tachycardia—Progesterone—uterine cancer	0.001	0.00263	CcSEcCtD
Dexmedetomidine—Pleural effusion—Doxorubicin—uterine cancer	0.000995	0.00262	CcSEcCtD
Dexmedetomidine—ADRA2C—uterus—uterine cancer	0.000992	0.0257	CbGeAlD
Dexmedetomidine—Hyperhidrosis—Progesterone—uterine cancer	0.00099	0.00261	CcSEcCtD
Dexmedetomidine—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.000986	0.0026	CcSEcCtD
Dexmedetomidine—CYP1A2—renal system—uterine cancer	0.000966	0.025	CbGeAlD
Dexmedetomidine—Anxiety—Medroxyprogesterone Acetate—uterine cancer	0.000965	0.00254	CcSEcCtD
Dexmedetomidine—Delirium—Epirubicin—uterine cancer	0.000957	0.00252	CcSEcCtD
Dexmedetomidine—Hypotension—Progesterone—uterine cancer	0.000957	0.00252	CcSEcCtD
Dexmedetomidine—CYP1A1—renal system—uterine cancer	0.000953	0.0247	CbGeAlD
Dexmedetomidine—ADRA2A—uterine cervix—uterine cancer	0.00095	0.0246	CbGeAlD
Dexmedetomidine—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.000947	0.00249	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Etoposide—uterine cancer	0.000941	0.00248	CcSEcCtD
Dexmedetomidine—Cardiovascular disorder—Epirubicin—uterine cancer	0.000937	0.00247	CcSEcCtD
Dexmedetomidine—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.000936	0.00247	CcSEcCtD
Dexmedetomidine—Rigors—Doxorubicin—uterine cancer	0.000933	0.00246	CcSEcCtD
Dexmedetomidine—Infection—Medroxyprogesterone Acetate—uterine cancer	0.000922	0.00243	CcSEcCtD
Dexmedetomidine—Chills—Dactinomycin—uterine cancer	0.000915	0.00241	CcSEcCtD
Dexmedetomidine—Dyspnoea—Progesterone—uterine cancer	0.000913	0.00241	CcSEcCtD
Dexmedetomidine—Somnolence—Progesterone—uterine cancer	0.000911	0.0024	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.000909	0.00239	CcSEcCtD
Dexmedetomidine—Bronchospasm—Etoposide—uterine cancer	0.000907	0.00239	CcSEcCtD
Dexmedetomidine—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.000906	0.00239	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Epirubicin—uterine cancer	0.000906	0.00239	CcSEcCtD
Dexmedetomidine—ADRA2A—decidua—uterine cancer	0.000905	0.0235	CbGeAlD
Dexmedetomidine—Hypocalcaemia—Epirubicin—uterine cancer	0.0009	0.00237	CcSEcCtD
Dexmedetomidine—Sweating increased—Etoposide—uterine cancer	0.000898	0.00236	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.000898	0.00236	CcSEcCtD
Dexmedetomidine—Oliguria—Epirubicin—uterine cancer	0.000894	0.00235	CcSEcCtD
Dexmedetomidine—CYP1A1—mammalian vulva—uterine cancer	0.000892	0.0231	CbGeAlD
Dexmedetomidine—Delirium—Doxorubicin—uterine cancer	0.000886	0.00233	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Progesterone—uterine cancer	0.000885	0.00233	CcSEcCtD
Dexmedetomidine—Pain—Progesterone—uterine cancer	0.000876	0.00231	CcSEcCtD
Dexmedetomidine—Constipation—Progesterone—uterine cancer	0.000876	0.00231	CcSEcCtD
Dexmedetomidine—CYP2E1—renal system—uterine cancer	0.000869	0.0225	CbGeAlD
Dexmedetomidine—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000868	0.00228	CcSEcCtD
Dexmedetomidine—Cardiovascular disorder—Doxorubicin—uterine cancer	0.000867	0.00228	CcSEcCtD
Dexmedetomidine—ADRA2A—endometrium—uterine cancer	0.000859	0.0223	CbGeAlD
Dexmedetomidine—CYP1A1—uterus—uterine cancer	0.000849	0.022	CbGeAlD
Dexmedetomidine—Atrioventricular block—Epirubicin—uterine cancer	0.000849	0.00224	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Progesterone—uterine cancer	0.000844	0.00222	CcSEcCtD
Dexmedetomidine—Hyperbilirubinaemia—Doxorubicin—uterine cancer	0.000838	0.00221	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Progesterone—uterine cancer	0.000838	0.00221	CcSEcCtD
Dexmedetomidine—Hypocalcaemia—Doxorubicin—uterine cancer	0.000832	0.00219	CcSEcCtD
Dexmedetomidine—ADRA2A—mammalian vulva—uterine cancer	0.000831	0.0215	CbGeAlD
Dexmedetomidine—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000828	0.00218	CcSEcCtD
Dexmedetomidine—Oliguria—Doxorubicin—uterine cancer	0.000827	0.00218	CcSEcCtD
Dexmedetomidine—Pneumonia—Etoposide—uterine cancer	0.000827	0.00218	CcSEcCtD
Dexmedetomidine—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000825	0.00217	CcSEcCtD
Dexmedetomidine—Phosphatase alkaline increased—Epirubicin—uterine cancer	0.000823	0.00217	CcSEcCtD
Dexmedetomidine—Ventricular tachycardia—Epirubicin—uterine cancer	0.000823	0.00217	CcSEcCtD
Dexmedetomidine—Anaemia—Dactinomycin—uterine cancer	0.00082	0.00216	CcSEcCtD
Dexmedetomidine—ADRA2C—female gonad—uterine cancer	0.000812	0.021	CbGeAlD
Dexmedetomidine—Acute coronary syndrome—Etoposide—uterine cancer	0.00081	0.00213	CcSEcCtD
Dexmedetomidine—Body temperature increased—Progesterone—uterine cancer	0.00081	0.00213	CcSEcCtD
Dexmedetomidine—Abdominal pain—Progesterone—uterine cancer	0.00081	0.00213	CcSEcCtD
Dexmedetomidine—Hyperkalaemia—Epirubicin—uterine cancer	0.000809	0.00213	CcSEcCtD
Dexmedetomidine—ADRA2C—vagina—uterine cancer	0.000807	0.0209	CbGeAlD
Dexmedetomidine—Myocardial infarction—Etoposide—uterine cancer	0.000806	0.00212	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Etoposide—uterine cancer	0.000806	0.00212	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000802	0.00211	CcSEcCtD
Dexmedetomidine—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000794	0.00209	CcSEcCtD
Dexmedetomidine—ADRA2A—uterus—uterine cancer	0.000792	0.0205	CbGeAlD
Dexmedetomidine—Atrioventricular block—Doxorubicin—uterine cancer	0.000786	0.00207	CcSEcCtD
Dexmedetomidine—Fluid retention—Epirubicin—uterine cancer	0.000782	0.00206	CcSEcCtD
Dexmedetomidine—Blood urea increased—Epirubicin—uterine cancer	0.000777	0.00205	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000765	0.00202	CcSEcCtD
Dexmedetomidine—CYP1A1—female reproductive system—uterine cancer	0.000763	0.0198	CbGeAlD
Dexmedetomidine—Phosphatase alkaline increased—Doxorubicin—uterine cancer	0.000762	0.00201	CcSEcCtD
Dexmedetomidine—Ventricular tachycardia—Doxorubicin—uterine cancer	0.000762	0.00201	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000759	0.002	CcSEcCtD
Dexmedetomidine—Hyperkalaemia—Doxorubicin—uterine cancer	0.000749	0.00197	CcSEcCtD
Dexmedetomidine—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000734	0.00193	CcSEcCtD
Dexmedetomidine—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000734	0.00193	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Epirubicin—uterine cancer	0.000733	0.00193	CcSEcCtD
Dexmedetomidine—Fluid retention—Doxorubicin—uterine cancer	0.000723	0.00191	CcSEcCtD
Dexmedetomidine—Infection—Dactinomycin—uterine cancer	0.000719	0.00189	CcSEcCtD
Dexmedetomidine—Blood urea increased—Doxorubicin—uterine cancer	0.000719	0.00189	CcSEcCtD
Dexmedetomidine—Abnormal vision—Epirubicin—uterine cancer	0.000718	0.00189	CcSEcCtD
Dexmedetomidine—Sepsis—Epirubicin—uterine cancer	0.000715	0.00188	CcSEcCtD
Dexmedetomidine—ADRA2A—female reproductive system—uterine cancer	0.000712	0.0184	CbGeAlD
Dexmedetomidine—Thrombocytopenia—Dactinomycin—uterine cancer	0.000709	0.00187	CcSEcCtD
Dexmedetomidine—Diarrhoea—Progesterone—uterine cancer	0.000701	0.00185	CcSEcCtD
Dexmedetomidine—CYP2E1—female reproductive system—uterine cancer	0.000696	0.018	CbGeAlD
Dexmedetomidine—CYP1A1—female gonad—uterine cancer	0.000695	0.018	CbGeAlD
Dexmedetomidine—CYP1A1—vagina—uterine cancer	0.000691	0.0179	CbGeAlD
Dexmedetomidine—CYP2D6—renal system—uterine cancer	0.000688	0.0178	CbGeAlD
Dexmedetomidine—Blood alkaline phosphatase increased—Epirubicin—uterine cancer	0.000687	0.00181	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Etoposide—uterine cancer	0.000685	0.0018	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Epirubicin—uterine cancer	0.000684	0.0018	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Doxorubicin—uterine cancer	0.000678	0.00179	CcSEcCtD
Dexmedetomidine—Dizziness—Progesterone—uterine cancer	0.000678	0.00178	CcSEcCtD
Dexmedetomidine—Angiopathy—Etoposide—uterine cancer	0.000669	0.00176	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Etoposide—uterine cancer	0.000665	0.00175	CcSEcCtD
Dexmedetomidine—Abnormal vision—Doxorubicin—uterine cancer	0.000665	0.00175	CcSEcCtD
Dexmedetomidine—Chills—Etoposide—uterine cancer	0.000662	0.00174	CcSEcCtD
Dexmedetomidine—Sepsis—Doxorubicin—uterine cancer	0.000661	0.00174	CcSEcCtD
Dexmedetomidine—Vomiting—Progesterone—uterine cancer	0.000651	0.00172	CcSEcCtD
Dexmedetomidine—ADRA2A—female gonad—uterine cancer	0.000648	0.0168	CbGeAlD
Dexmedetomidine—Renal failure acute—Epirubicin—uterine cancer	0.000647	0.00171	CcSEcCtD
Dexmedetomidine—Rash—Progesterone—uterine cancer	0.000646	0.0017	CcSEcCtD
Dexmedetomidine—Dermatitis—Progesterone—uterine cancer	0.000645	0.0017	CcSEcCtD
Dexmedetomidine—ADRA2A—vagina—uterine cancer	0.000644	0.0167	CbGeAlD
Dexmedetomidine—Headache—Progesterone—uterine cancer	0.000642	0.00169	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.000636	0.00167	CcSEcCtD
Dexmedetomidine—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000635	0.00167	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Doxorubicin—uterine cancer	0.000633	0.00167	CcSEcCtD
Dexmedetomidine—Pain—Dactinomycin—uterine cancer	0.000619	0.00163	CcSEcCtD
Dexmedetomidine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000614	0.00162	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Epirubicin—uterine cancer	0.000612	0.00161	CcSEcCtD
Dexmedetomidine—Nausea—Progesterone—uterine cancer	0.000609	0.0016	CcSEcCtD
Dexmedetomidine—Renal failure acute—Doxorubicin—uterine cancer	0.000599	0.00158	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Dactinomycin—uterine cancer	0.000597	0.00157	CcSEcCtD
Dexmedetomidine—Anaemia—Etoposide—uterine cancer	0.000594	0.00156	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000592	0.00156	CcSEcCtD
Dexmedetomidine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00059	0.00155	CcSEcCtD
Dexmedetomidine—SLC6A2—lymph node—uterine cancer	0.000589	0.0153	CbGeAlD
Dexmedetomidine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000585	0.00154	CcSEcCtD
Dexmedetomidine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000585	0.00154	CcSEcCtD
Dexmedetomidine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000582	0.00153	CcSEcCtD
Dexmedetomidine—Abdominal pain—Dactinomycin—uterine cancer	0.000572	0.00151	CcSEcCtD
Dexmedetomidine—Body temperature increased—Dactinomycin—uterine cancer	0.000572	0.00151	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Epirubicin—uterine cancer	0.000568	0.0015	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Doxorubicin—uterine cancer	0.000567	0.00149	CcSEcCtD
Dexmedetomidine—Convulsion—Etoposide—uterine cancer	0.000556	0.00147	CcSEcCtD
Dexmedetomidine—Hypertension—Etoposide—uterine cancer	0.000554	0.00146	CcSEcCtD
Dexmedetomidine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000551	0.00145	CcSEcCtD
Dexmedetomidine—CYP2D6—female reproductive system—uterine cancer	0.000551	0.0143	CbGeAlD
Dexmedetomidine—Hypokalaemia—Epirubicin—uterine cancer	0.000544	0.00143	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000538	0.00142	CcSEcCtD
Dexmedetomidine—Confusional state—Etoposide—uterine cancer	0.000528	0.00139	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000527	0.00139	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Doxorubicin—uterine cancer	0.000526	0.00139	CcSEcCtD
Dexmedetomidine—ADRA2C—lymph node—uterine cancer	0.000522	0.0135	CbGeAlD
Dexmedetomidine—Infection—Etoposide—uterine cancer	0.000521	0.00137	CcSEcCtD
Dexmedetomidine—Abdominal distension—Epirubicin—uterine cancer	0.00052	0.00137	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Etoposide—uterine cancer	0.000513	0.00135	CcSEcCtD
Dexmedetomidine—Tachycardia—Etoposide—uterine cancer	0.000512	0.00135	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Etoposide—uterine cancer	0.000507	0.00133	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Doxorubicin—uterine cancer	0.000503	0.00133	CcSEcCtD
Dexmedetomidine—CYP2D6—female gonad—uterine cancer	0.000502	0.013	CbGeAlD
Dexmedetomidine—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000498	0.00131	CcSEcCtD
Dexmedetomidine—Diarrhoea—Dactinomycin—uterine cancer	0.000495	0.0013	CcSEcCtD
Dexmedetomidine—Hypotension—Etoposide—uterine cancer	0.00049	0.00129	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000488	0.00128	CcSEcCtD
Dexmedetomidine—Abdominal distension—Doxorubicin—uterine cancer	0.000481	0.00127	CcSEcCtD
Dexmedetomidine—Dyspnoea—Etoposide—uterine cancer	0.000467	0.00123	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Epirubicin—uterine cancer	0.000466	0.00123	CcSEcCtD
Dexmedetomidine—Somnolence—Etoposide—uterine cancer	0.000466	0.00123	CcSEcCtD
Dexmedetomidine—Pneumonia—Epirubicin—uterine cancer	0.000463	0.00122	CcSEcCtD
Dexmedetomidine—Vomiting—Dactinomycin—uterine cancer	0.00046	0.00121	CcSEcCtD
Dexmedetomidine—Rash—Dactinomycin—uterine cancer	0.000457	0.0012	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000452	0.00119	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Epirubicin—uterine cancer	0.000452	0.00119	CcSEcCtD
Dexmedetomidine—Pain—Etoposide—uterine cancer	0.000448	0.00118	CcSEcCtD
Dexmedetomidine—Constipation—Etoposide—uterine cancer	0.000448	0.00118	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Epirubicin—uterine cancer	0.000448	0.00118	CcSEcCtD
Dexmedetomidine—CYP1A1—lymph node—uterine cancer	0.000447	0.0116	CbGeAlD
Dexmedetomidine—Feeling abnormal—Etoposide—uterine cancer	0.000432	0.00114	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Doxorubicin—uterine cancer	0.000431	0.00114	CcSEcCtD
Dexmedetomidine—Nausea—Dactinomycin—uterine cancer	0.00043	0.00113	CcSEcCtD
Dexmedetomidine—Pneumonia—Doxorubicin—uterine cancer	0.000429	0.00113	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Etoposide—uterine cancer	0.000429	0.00113	CcSEcCtD
Dexmedetomidine—Bradycardia—Epirubicin—uterine cancer	0.000421	0.00111	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000418	0.0011	CcSEcCtD
Dexmedetomidine—ADRA2A—lymph node—uterine cancer	0.000416	0.0108	CbGeAlD
Dexmedetomidine—Haemoglobin—Epirubicin—uterine cancer	0.000416	0.00109	CcSEcCtD
Dexmedetomidine—Body temperature increased—Etoposide—uterine cancer	0.000414	0.00109	CcSEcCtD
Dexmedetomidine—Abdominal pain—Etoposide—uterine cancer	0.000414	0.00109	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Doxorubicin—uterine cancer	0.000414	0.00109	CcSEcCtD
Dexmedetomidine—Haemorrhage—Epirubicin—uterine cancer	0.000414	0.00109	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Epirubicin—uterine cancer	0.000407	0.00107	CcSEcCtD
Dexmedetomidine—Visual impairment—Epirubicin—uterine cancer	0.000399	0.00105	CcSEcCtD
Dexmedetomidine—Bradycardia—Doxorubicin—uterine cancer	0.00039	0.00103	CcSEcCtD
Dexmedetomidine—Haemoglobin—Doxorubicin—uterine cancer	0.000385	0.00101	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Epirubicin—uterine cancer	0.000384	0.00101	CcSEcCtD
Dexmedetomidine—Haemorrhage—Doxorubicin—uterine cancer	0.000383	0.00101	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Doxorubicin—uterine cancer	0.000377	0.000993	CcSEcCtD
Dexmedetomidine—Angiopathy—Epirubicin—uterine cancer	0.000375	0.000988	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Epirubicin—uterine cancer	0.000373	0.000982	CcSEcCtD
Dexmedetomidine—Chills—Epirubicin—uterine cancer	0.000371	0.000977	CcSEcCtD
Dexmedetomidine—Arrhythmia—Epirubicin—uterine cancer	0.000369	0.000973	CcSEcCtD
Dexmedetomidine—Visual impairment—Doxorubicin—uterine cancer	0.000369	0.000971	CcSEcCtD
Dexmedetomidine—Mental disorder—Epirubicin—uterine cancer	0.000362	0.000954	CcSEcCtD
Dexmedetomidine—Malnutrition—Epirubicin—uterine cancer	0.00036	0.000948	CcSEcCtD
Dexmedetomidine—Diarrhoea—Etoposide—uterine cancer	0.000359	0.000944	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Doxorubicin—uterine cancer	0.000355	0.000935	CcSEcCtD
Dexmedetomidine—Angiopathy—Doxorubicin—uterine cancer	0.000347	0.000914	CcSEcCtD
Dexmedetomidine—Dizziness—Etoposide—uterine cancer	0.000347	0.000913	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Doxorubicin—uterine cancer	0.000345	0.000908	CcSEcCtD
Dexmedetomidine—Chills—Doxorubicin—uterine cancer	0.000343	0.000904	CcSEcCtD
Dexmedetomidine—Arrhythmia—Doxorubicin—uterine cancer	0.000342	0.0009	CcSEcCtD
Dexmedetomidine—Mental disorder—Doxorubicin—uterine cancer	0.000335	0.000883	CcSEcCtD
Dexmedetomidine—Vomiting—Etoposide—uterine cancer	0.000333	0.000878	CcSEcCtD
Dexmedetomidine—Malnutrition—Doxorubicin—uterine cancer	0.000333	0.000877	CcSEcCtD
Dexmedetomidine—Anaemia—Epirubicin—uterine cancer	0.000333	0.000876	CcSEcCtD
Dexmedetomidine—Agitation—Epirubicin—uterine cancer	0.000331	0.000871	CcSEcCtD
Dexmedetomidine—Rash—Etoposide—uterine cancer	0.00033	0.00087	CcSEcCtD
Dexmedetomidine—Dermatitis—Etoposide—uterine cancer	0.00033	0.00087	CcSEcCtD
Dexmedetomidine—Headache—Etoposide—uterine cancer	0.000328	0.000865	CcSEcCtD
Dexmedetomidine—Convulsion—Epirubicin—uterine cancer	0.000312	0.000821	CcSEcCtD
Dexmedetomidine—Nausea—Etoposide—uterine cancer	0.000311	0.00082	CcSEcCtD
Dexmedetomidine—Hypertension—Epirubicin—uterine cancer	0.000311	0.000819	CcSEcCtD
Dexmedetomidine—Anaemia—Doxorubicin—uterine cancer	0.000308	0.000811	CcSEcCtD
Dexmedetomidine—Agitation—Doxorubicin—uterine cancer	0.000306	0.000806	CcSEcCtD
Dexmedetomidine—Anxiety—Epirubicin—uterine cancer	0.000305	0.000804	CcSEcCtD
Dexmedetomidine—Dry mouth—Epirubicin—uterine cancer	0.0003	0.000789	CcSEcCtD
Dexmedetomidine—Confusional state—Epirubicin—uterine cancer	0.000296	0.00078	CcSEcCtD
Dexmedetomidine—Infection—Epirubicin—uterine cancer	0.000292	0.000769	CcSEcCtD
Dexmedetomidine—Convulsion—Doxorubicin—uterine cancer	0.000289	0.00076	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Epirubicin—uterine cancer	0.000288	0.000758	CcSEcCtD
Dexmedetomidine—Hypertension—Doxorubicin—uterine cancer	0.000288	0.000757	CcSEcCtD
Dexmedetomidine—Tachycardia—Epirubicin—uterine cancer	0.000287	0.000755	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Epirubicin—uterine cancer	0.000284	0.000748	CcSEcCtD
Dexmedetomidine—Anxiety—Doxorubicin—uterine cancer	0.000283	0.000744	CcSEcCtD
Dexmedetomidine—Dry mouth—Doxorubicin—uterine cancer	0.000277	0.00073	CcSEcCtD
Dexmedetomidine—Hypotension—Epirubicin—uterine cancer	0.000275	0.000723	CcSEcCtD
Dexmedetomidine—Confusional state—Doxorubicin—uterine cancer	0.000274	0.000722	CcSEcCtD
Dexmedetomidine—Infection—Doxorubicin—uterine cancer	0.00027	0.000711	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Doxorubicin—uterine cancer	0.000266	0.000701	CcSEcCtD
Dexmedetomidine—Tachycardia—Doxorubicin—uterine cancer	0.000265	0.000699	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Doxorubicin—uterine cancer	0.000263	0.000692	CcSEcCtD
Dexmedetomidine—Dyspnoea—Epirubicin—uterine cancer	0.000262	0.00069	CcSEcCtD
Dexmedetomidine—Somnolence—Epirubicin—uterine cancer	0.000261	0.000688	CcSEcCtD
Dexmedetomidine—Hypotension—Doxorubicin—uterine cancer	0.000254	0.000669	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000254	0.000668	CcSEcCtD
Dexmedetomidine—Pain—Epirubicin—uterine cancer	0.000251	0.000662	CcSEcCtD
Dexmedetomidine—Constipation—Epirubicin—uterine cancer	0.000251	0.000662	CcSEcCtD
Dexmedetomidine—Dyspnoea—Doxorubicin—uterine cancer	0.000242	0.000638	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Epirubicin—uterine cancer	0.000242	0.000638	CcSEcCtD
Dexmedetomidine—Somnolence—Doxorubicin—uterine cancer	0.000242	0.000637	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Epirubicin—uterine cancer	0.00024	0.000633	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000235	0.000618	CcSEcCtD
Dexmedetomidine—Constipation—Doxorubicin—uterine cancer	0.000232	0.000612	CcSEcCtD
Dexmedetomidine—Pain—Doxorubicin—uterine cancer	0.000232	0.000612	CcSEcCtD
Dexmedetomidine—Abdominal pain—Epirubicin—uterine cancer	0.000232	0.000612	CcSEcCtD
Dexmedetomidine—Body temperature increased—Epirubicin—uterine cancer	0.000232	0.000612	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Doxorubicin—uterine cancer	0.000224	0.00059	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000222	0.000585	CcSEcCtD
Dexmedetomidine—Abdominal pain—Doxorubicin—uterine cancer	0.000215	0.000566	CcSEcCtD
Dexmedetomidine—Body temperature increased—Doxorubicin—uterine cancer	0.000215	0.000566	CcSEcCtD
Dexmedetomidine—Diarrhoea—Epirubicin—uterine cancer	0.000201	0.000529	CcSEcCtD
Dexmedetomidine—Dizziness—Epirubicin—uterine cancer	0.000194	0.000512	CcSEcCtD
Dexmedetomidine—Vomiting—Epirubicin—uterine cancer	0.000187	0.000492	CcSEcCtD
Dexmedetomidine—Diarrhoea—Doxorubicin—uterine cancer	0.000186	0.00049	CcSEcCtD
Dexmedetomidine—Rash—Epirubicin—uterine cancer	0.000185	0.000488	CcSEcCtD
Dexmedetomidine—Dermatitis—Epirubicin—uterine cancer	0.000185	0.000487	CcSEcCtD
Dexmedetomidine—Headache—Epirubicin—uterine cancer	0.000184	0.000485	CcSEcCtD
Dexmedetomidine—Dizziness—Doxorubicin—uterine cancer	0.00018	0.000473	CcSEcCtD
Dexmedetomidine—Nausea—Epirubicin—uterine cancer	0.000175	0.00046	CcSEcCtD
Dexmedetomidine—Vomiting—Doxorubicin—uterine cancer	0.000173	0.000455	CcSEcCtD
Dexmedetomidine—Rash—Doxorubicin—uterine cancer	0.000171	0.000451	CcSEcCtD
Dexmedetomidine—Dermatitis—Doxorubicin—uterine cancer	0.000171	0.000451	CcSEcCtD
Dexmedetomidine—Headache—Doxorubicin—uterine cancer	0.00017	0.000449	CcSEcCtD
Dexmedetomidine—Nausea—Doxorubicin—uterine cancer	0.000161	0.000425	CcSEcCtD
Dexmedetomidine—ADRA2C—Metabolism—STK11—uterine cancer	5.89e-07	0.000748	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CYP19A1—uterine cancer	5.89e-07	0.000748	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—YWHAE—uterine cancer	5.88e-07	0.000747	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—VEGFA—uterine cancer	5.88e-07	0.000746	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STK11—uterine cancer	5.84e-07	0.000742	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CCL2—uterine cancer	5.82e-07	0.000739	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—NRAS—uterine cancer	5.8e-07	0.000737	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—EP300—uterine cancer	5.79e-07	0.000736	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—YWHAE—uterine cancer	5.79e-07	0.000735	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKR1C3—uterine cancer	5.64e-07	0.000716	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FBXW7—uterine cancer	5.64e-07	0.000716	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYP11A1—uterine cancer	5.63e-07	0.000715	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—POLD1—uterine cancer	5.56e-07	0.000706	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FBXW7—uterine cancer	5.55e-07	0.000705	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—uterine cancer	5.52e-07	0.000701	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—VEGFA—uterine cancer	5.49e-07	0.000697	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SOCS3—uterine cancer	5.47e-07	0.000695	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—NRAS—uterine cancer	5.42e-07	0.000688	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKR1C3—uterine cancer	5.32e-07	0.000675	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STK11—uterine cancer	5.28e-07	0.00067	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CCL2—uterine cancer	5.25e-07	0.000667	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN2B—uterine cancer	5.24e-07	0.000665	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKR1C1—uterine cancer	5.2e-07	0.00066	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKR1C3—uterine cancer	5.14e-07	0.000652	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IGF1R—uterine cancer	5.09e-07	0.000646	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—CXCL8—uterine cancer	5.06e-07	0.000643	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PGR—uterine cancer	5.01e-07	0.000636	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—KRAS—uterine cancer	4.99e-07	0.000634	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SOCS3—uterine cancer	4.94e-07	0.000627	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STK11—uterine cancer	4.93e-07	0.000626	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CCL2—uterine cancer	4.9e-07	0.000623	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STK11—uterine cancer	4.85e-07	0.000616	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CCL2—uterine cancer	4.83e-07	0.000613	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CYP19A1—uterine cancer	4.79e-07	0.000608	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—STK11—uterine cancer	4.79e-07	0.000608	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SMAD3—uterine cancer	4.78e-07	0.000607	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—YWHAE—uterine cancer	4.78e-07	0.000607	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN2B—uterine cancer	4.73e-07	0.000601	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—POLD1—uterine cancer	4.71e-07	0.000598	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—EP300—uterine cancer	4.71e-07	0.000598	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—KRAS—uterine cancer	4.67e-07	0.000592	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—RRM2—uterine cancer	4.64e-07	0.000589	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SOCS3—uterine cancer	4.61e-07	0.000586	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CXCL8—uterine cancer	4.6e-07	0.000584	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IGF1R—uterine cancer	4.59e-07	0.000583	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—PIK3CA—uterine cancer	4.59e-07	0.000583	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FBXW7—uterine cancer	4.58e-07	0.000581	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CXCL8—uterine cancer	4.57e-07	0.000581	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—FGFR2—uterine cancer	4.56e-07	0.000579	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SOCS3—uterine cancer	4.54e-07	0.000577	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—DCN—uterine cancer	4.5e-07	0.000571	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—VEGFA—uterine cancer	4.46e-07	0.000566	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—TP53—uterine cancer	4.44e-07	0.000564	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—MTHFR—uterine cancer	4.43e-07	0.000562	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN2B—uterine cancer	4.42e-07	0.000561	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKR1C1—uterine cancer	4.41e-07	0.000559	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—NRAS—uterine cancer	4.4e-07	0.000559	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CYP19A1—uterine cancer	4.4e-07	0.000558	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—STK11—uterine cancer	4.4e-07	0.000558	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN2B—uterine cancer	4.35e-07	0.000552	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SMAD3—uterine cancer	4.32e-07	0.000548	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IGF1R—uterine cancer	4.29e-07	0.000545	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—PIK3CA—uterine cancer	4.29e-07	0.000544	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CXCL8—uterine cancer	4.27e-07	0.000542	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—HRAS—uterine cancer	4.25e-07	0.000539	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP11A1—uterine cancer	4.24e-07	0.000538	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IGF1R—uterine cancer	4.22e-07	0.000536	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CXCL8—uterine cancer	4.2e-07	0.000534	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CXCL8—uterine cancer	4.15e-07	0.000527	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—TP53—uterine cancer	4.15e-07	0.000527	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—STK11—uterine cancer	4.14e-07	0.000526	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CYP19A1—uterine cancer	4.14e-07	0.000526	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—FGFR2—uterine cancer	4.12e-07	0.000523	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SMAD3—uterine cancer	4.03e-07	0.000512	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKR1C3—uterine cancer	4e-07	0.000508	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STK11—uterine cancer	4e-07	0.000508	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CCL2—uterine cancer	3.98e-07	0.000506	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SMAD3—uterine cancer	3.97e-07	0.000504	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—HRAS—uterine cancer	3.97e-07	0.000504	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—RRM2—uterine cancer	3.93e-07	0.000499	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ESR1—uterine cancer	3.9e-07	0.000496	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.89e-07	0.000494	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CXCL8—uterine cancer	3.88e-07	0.000492	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FGFR2—uterine cancer	3.85e-07	0.000488	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CXCL8—uterine cancer	3.82e-07	0.000485	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—DCN—uterine cancer	3.81e-07	0.000484	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—KRAS—uterine cancer	3.79e-07	0.000481	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FGFR2—uterine cancer	3.79e-07	0.000481	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—AKT1—uterine cancer	3.75e-07	0.000476	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SOCS3—uterine cancer	3.75e-07	0.000476	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.71e-07	0.000471	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—NRAS—uterine cancer	3.69e-07	0.000468	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—MTHFR—uterine cancer	3.6e-07	0.000457	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP11A1—uterine cancer	3.59e-07	0.000456	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN2B—uterine cancer	3.59e-07	0.000456	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ESR1—uterine cancer	3.52e-07	0.000447	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—AKT1—uterine cancer	3.5e-07	0.000445	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF1R—uterine cancer	3.48e-07	0.000442	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—PIK3CA—uterine cancer	3.48e-07	0.000442	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CXCL8—uterine cancer	3.47e-07	0.00044	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCL2—uterine cancer	3.44e-07	0.000436	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKR1C3—uterine cancer	3.39e-07	0.000431	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—uterine cancer	3.37e-07	0.000428	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—NRAS—uterine cancer	3.33e-07	0.000423	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—MTHFR—uterine cancer	3.3e-07	0.000419	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ESR1—uterine cancer	3.29e-07	0.000418	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SMAD3—uterine cancer	3.28e-07	0.000416	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ESR1—uterine cancer	3.24e-07	0.000411	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—HRAS—uterine cancer	3.22e-07	0.000409	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—PIK3CA—uterine cancer	3.21e-07	0.000408	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—KRAS—uterine cancer	3.18e-07	0.000403	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CXCL8—uterine cancer	3.15e-07	0.0004	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FGFR2—uterine cancer	3.12e-07	0.000397	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CYP19A1—uterine cancer	3.12e-07	0.000396	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—STK11—uterine cancer	3.12e-07	0.000396	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—MTHFR—uterine cancer	3.11e-07	0.000395	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—NRAS—uterine cancer	3.11e-07	0.000395	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCL2—uterine cancer	3.1e-07	0.000394	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—NRAS—uterine cancer	3.06e-07	0.000389	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—PIK3CA—uterine cancer	2.92e-07	0.00037	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—PIK3CA—uterine cancer	2.9e-07	0.000368	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCL2—uterine cancer	2.9e-07	0.000368	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—KRAS—uterine cancer	2.87e-07	0.000364	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ERBB2—uterine cancer	2.86e-07	0.000364	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCL2—uterine cancer	2.85e-07	0.000362	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—AKT1—uterine cancer	2.84e-07	0.000361	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.74e-07	0.000348	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCL8—uterine cancer	2.72e-07	0.000345	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CA—uterine cancer	2.71e-07	0.000344	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—HRAS—uterine cancer	2.7e-07	0.000343	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—KRAS—uterine cancer	2.68e-07	0.00034	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ESR1—uterine cancer	2.67e-07	0.000339	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CA—uterine cancer	2.67e-07	0.000339	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1B—uterine cancer	2.65e-07	0.000337	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—STK11—uterine cancer	2.64e-07	0.000336	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CYP19A1—uterine cancer	2.64e-07	0.000336	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—KRAS—uterine cancer	2.64e-07	0.000335	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—uterine cancer	2.63e-07	0.000334	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKT1—uterine cancer	2.62e-07	0.000333	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ERBB2—uterine cancer	2.59e-07	0.000328	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—NRAS—uterine cancer	2.53e-07	0.000321	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CTNNB1—uterine cancer	2.51e-07	0.000318	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.48e-07	0.000315	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTEN—uterine cancer	2.46e-07	0.000313	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—uterine cancer	2.46e-07	0.000312	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL8—uterine cancer	2.45e-07	0.000311	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTEN—uterine cancer	2.44e-07	0.00031	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HRAS—uterine cancer	2.44e-07	0.000309	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—uterine cancer	2.42e-07	0.000307	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ERBB2—uterine cancer	2.42e-07	0.000307	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1B—uterine cancer	2.39e-07	0.000304	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKT1—uterine cancer	2.38e-07	0.000303	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ERBB2—uterine cancer	2.38e-07	0.000302	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKT1—uterine cancer	2.37e-07	0.000301	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.37e-07	0.0003	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCL2—uterine cancer	2.35e-07	0.000299	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—EP300—uterine cancer	2.35e-07	0.000298	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—MTHFR—uterine cancer	2.34e-07	0.000298	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EP300—uterine cancer	2.33e-07	0.000296	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL8—uterine cancer	2.29e-07	0.000291	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HRAS—uterine cancer	2.28e-07	0.000289	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CTNNB1—uterine cancer	2.26e-07	0.000287	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL8—uterine cancer	2.25e-07	0.000286	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HRAS—uterine cancer	2.24e-07	0.000284	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1B—uterine cancer	2.24e-07	0.000284	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKT1—uterine cancer	2.21e-07	0.000281	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—uterine cancer	2.21e-07	0.00028	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTEN—uterine cancer	2.21e-07	0.00028	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1B—uterine cancer	2.2e-07	0.00028	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—uterine cancer	2.2e-07	0.000279	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NRAS—uterine cancer	2.18e-07	0.000277	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKT1—uterine cancer	2.18e-07	0.000277	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—KRAS—uterine cancer	2.17e-07	0.000276	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKT1—uterine cancer	2.15e-07	0.000273	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CTNNB1—uterine cancer	2.11e-07	0.000268	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EP300—uterine cancer	2.1e-07	0.000267	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CTNNB1—uterine cancer	2.08e-07	0.000264	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTEN—uterine cancer	2.06e-07	0.000262	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTEN—uterine cancer	2.03e-07	0.000257	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKT1—uterine cancer	2.01e-07	0.000255	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTEN—uterine cancer	2e-07	0.000254	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—uterine cancer	2e-07	0.000254	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—uterine cancer	1.99e-07	0.000253	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—MTHFR—uterine cancer	1.99e-07	0.000252	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKT1—uterine cancer	1.98e-07	0.000251	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NRAS—uterine cancer	1.97e-07	0.00025	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EP300—uterine cancer	1.96e-07	0.000249	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ERBB2—uterine cancer	1.96e-07	0.000249	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EP300—uterine cancer	1.93e-07	0.000246	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—EP300—uterine cancer	1.91e-07	0.000242	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KRAS—uterine cancer	1.88e-07	0.000238	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL8—uterine cancer	1.86e-07	0.000236	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—uterine cancer	1.86e-07	0.000236	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HRAS—uterine cancer	1.85e-07	0.000235	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NRAS—uterine cancer	1.84e-07	0.000233	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTEN—uterine cancer	1.84e-07	0.000233	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—uterine cancer	1.83e-07	0.000233	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1B—uterine cancer	1.82e-07	0.000231	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NRAS—uterine cancer	1.81e-07	0.00023	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKT1—uterine cancer	1.8e-07	0.000228	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—EP300—uterine cancer	1.75e-07	0.000223	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.75e-07	0.000222	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—uterine cancer	1.74e-07	0.000221	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTEN—uterine cancer	1.73e-07	0.00022	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—uterine cancer	1.72e-07	0.000219	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CTNNB1—uterine cancer	1.72e-07	0.000218	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KRAS—uterine cancer	1.69e-07	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTEN—uterine cancer	1.67e-07	0.000212	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—uterine cancer	1.67e-07	0.000212	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—EP300—uterine cancer	1.65e-07	0.00021	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKT1—uterine cancer	1.63e-07	0.000207	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EP300—uterine cancer	1.6e-07	0.000203	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HRAS—uterine cancer	1.59e-07	0.000202	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KRAS—uterine cancer	1.58e-07	0.000201	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KRAS—uterine cancer	1.56e-07	0.000198	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—uterine cancer	1.56e-07	0.000198	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—uterine cancer	1.51e-07	0.000192	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—uterine cancer	1.51e-07	0.000191	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NRAS—uterine cancer	1.49e-07	0.00019	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—uterine cancer	1.45e-07	0.000185	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HRAS—uterine cancer	1.44e-07	0.000183	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—uterine cancer	1.43e-07	0.000182	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AKT1—uterine cancer	1.42e-07	0.00018	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—uterine cancer	1.41e-07	0.000179	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT1—uterine cancer	1.41e-07	0.000179	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—uterine cancer	1.41e-07	0.000179	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—uterine cancer	1.38e-07	0.000176	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HRAS—uterine cancer	1.34e-07	0.000171	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HRAS—uterine cancer	1.32e-07	0.000168	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTEN—uterine cancer	1.3e-07	0.000166	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—uterine cancer	1.3e-07	0.000165	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KRAS—uterine cancer	1.28e-07	0.000163	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT1—uterine cancer	1.27e-07	0.000161	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—EP300—uterine cancer	1.24e-07	0.000158	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—uterine cancer	1.22e-07	0.000155	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT1—uterine cancer	1.19e-07	0.000151	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—uterine cancer	1.18e-07	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT1—uterine cancer	1.17e-07	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AKT1—uterine cancer	1.15e-07	0.000146	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—uterine cancer	1.14e-07	0.000145	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTEN—uterine cancer	1.1e-07	0.00014	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HRAS—uterine cancer	1.09e-07	0.000139	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKT1—uterine cancer	1.06e-07	0.000134	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—EP300—uterine cancer	1.05e-07	0.000134	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKT1—uterine cancer	9.98e-08	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT1—uterine cancer	9.64e-08	0.000122	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—uterine cancer	9.2e-08	0.000117	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—uterine cancer	7.79e-08	9.9e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKT1—uterine cancer	7.51e-08	9.54e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKT1—uterine cancer	6.37e-08	8.08e-05	CbGpPWpGaD
